gamma-aminobutyric acid has been researched along with Kidney Neoplasms in 6 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Kidney Neoplasms: Tumors or cancers of the KIDNEY.
Excerpt | Relevance | Reference |
---|---|---|
"In the renal cell carcinoma, in contrast with GBM, (13) C multiplets of γ-aminobutyric acid (GABA) differed from its precursor glutamate, suggesting that GABA did not derive from a common glutamate precursor pool." | 1.38 | Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors. ( Bachoo, RM; Cho, SK; Choi, C; Deberardinis, RJ; Good, LB; Hatanpaa, KJ; Jindal, A; Kapur, P; Maher, EA; Malloy, CR; Marin-Valencia, I; Mashimo, T; Mickey, B; Pascual, JM; Raisanen, J; Rakheja, D; Sun, X; Takahashi, M; Togao, O; Vemireddy, V, 2012) |
"Gamma-aminobutyric acid (GABA) was first discovered as an inhibitory neurotransmitter in the central nervous system (CNS) and has been reported to have a variety of functions, including regulation of cell division, cell differentiation and maturation, and to be involved in the development of certain cancers outside the CNS." | 1.34 | Invasive ability of human renal cell carcinoma cell line Caki-2 is accelerated by gamma-aminobutyric acid, via sustained activation of ERK1/2 inducible matrix metalloproteinases. ( Azuma, H; Inamoto, T; Katsuoka, Y; Kiyama, S; Kotake, Y; Sakamoto, T; Ubai, T; Watanabe, M, 2007) |
"In the present study, using the human renal cell carcinoma cell line Caki-2, we demonstrated that GABA stimulation significantly increased the expression of MMP-2 and -9 and subsequently increased the invasive activity of the cancer cells." | 1.34 | Invasive ability of human renal cell carcinoma cell line Caki-2 is accelerated by gamma-aminobutyric acid, via sustained activation of ERK1/2 inducible matrix metalloproteinases. ( Azuma, H; Inamoto, T; Katsuoka, Y; Kiyama, S; Kotake, Y; Sakamoto, T; Ubai, T; Watanabe, M, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Marin-Valencia, I | 1 |
Cho, SK | 1 |
Rakheja, D | 1 |
Hatanpaa, KJ | 1 |
Kapur, P | 1 |
Mashimo, T | 1 |
Jindal, A | 1 |
Vemireddy, V | 1 |
Good, LB | 1 |
Raisanen, J | 1 |
Sun, X | 1 |
Mickey, B | 1 |
Choi, C | 1 |
Takahashi, M | 1 |
Togao, O | 1 |
Pascual, JM | 1 |
Deberardinis, RJ | 1 |
Maher, EA | 1 |
Malloy, CR | 1 |
Bachoo, RM | 1 |
Nakashima, T | 1 |
Kiba, T | 1 |
Ogawa, Y | 1 |
Hosokawa, A | 1 |
Shintani, H | 1 |
Okada, Y | 1 |
Taniguchi, T | 1 |
Shigeta, M | 1 |
Kozawa, K | 1 |
Oefelein, MG | 1 |
Bayazit, Y | 1 |
Inamoto, T | 1 |
Azuma, H | 1 |
Sakamoto, T | 1 |
Kiyama, S | 1 |
Ubai, T | 1 |
Kotake, Y | 1 |
Watanabe, M | 1 |
Katsuoka, Y | 1 |
de la Iglesia, FA | 1 |
Gough, AW | 2 |
Sigler, RE | 2 |
Dominick, MA | 1 |
Robertson, DG | 1 |
Bleavins, MR | 1 |
Bobrowski, WF | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Treatment Development of Triheptanoin for Glucose Transporter Type I Deficiency[NCT02021526] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn (stopped due to NIH funding resulted in new clinical trial) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
6 other studies available for gamma-aminobutyric acid and Kidney Neoplasms
Article | Year |
---|---|
Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors.
Topics: Animals; Brain Neoplasms; Carcinoma, Renal Cell; Citric Acid Cycle; Disease Models, Animal; gamma-Am | 2012 |
[A case of paclitaxel-induced peripheral neuropathy successfully treated with pregabalin].
Topics: Antineoplastic Combined Chemotherapy Protocols; gamma-Aminobutyric Acid; Humans; Kidney Neoplasms; M | 2012 |
Chronic pain syndrome after laparoscopic radical nephrectomy.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Carcinoma, Renal Cell; Carcinoma, Transition | 2003 |
Invasive ability of human renal cell carcinoma cell line Caki-2 is accelerated by gamma-aminobutyric acid, via sustained activation of ERK1/2 inducible matrix metalloproteinases.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Enzyme Activation; gamma-Aminobutyric Acid; Humans; Kidney | 2007 |
alpha2u-Globulin nephropathy and ravens: do ravens of a different feather flock together?
Topics: Acetates; Alpha-Globulins; Amines; Animals; Anticonvulsants; Carcinogenicity Tests; Cyclohexanecarbo | 1997 |
Alpha 2u-globulin nephropathy without nephrocarcinogenesis in male Wistar rats administered 1-(aminomethyl)cyclohexaneacetic acid.
Topics: Acetates; Alpha-Globulins; Amines; Animals; Chromatography, Gel; Cyclohexanecarboxylic Acids; Dose-R | 1991 |